Abstract

This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The Alzheimer's Disease Prevention Trial with Estrogens was designed to test the safety and efficacy of hormone replacement therapy in delaying the onset of Alzheimer's disease (AD) and memory loss in women over age 65 who have a family history of AD. As originally funded, the protocol was randomized, double blind placebo controlled parallel group design with stratification by hysterectomy status and geographic center; study medication was Premarin (0.625mg) or Prempro (0.625 mg Premarin plus 2.5 mg medroxyprogesterone acetate) for those who had an intact uterus. As described below, findings published in May 2003 from the Women's Health Initiative Memory Study (WHIMS) necessitated changes to the protocol and study design of the AD Prevential Trial with Estrogens.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR010284-13
Application #
7718999
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2008-03-01
Project End
2009-02-28
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
13
Fiscal Year
2008
Total Cost
$3,246
Indirect Cost

  Institution

Name
Howard University
Department
Type
Schools of Medicine
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059

  Publications

Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Doumatey, Ayo P; He, William J; Gaye, Amadou et al. (2018) Circulating MiR-374a-5p is a potential modulator of the inflammatory process in obesity. Sci Rep 8:7680
Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823
Mullins, Tanya L Kowalczyk; Li, Su X; Bethel, James et al. (2018) Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. J Clin Virol 102:7-11
Faruque, Mezbah U; Chen, Guanjie; Doumatey, Ayo P et al. (2017) Transferability of genome-wide associated loci for asthma in African Americans. J Asthma 54:1-8
Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935
Nandakumar, Priyanka; Lee, Dongwon; Richard, Melissa A et al. (2017) Rare coding variants associated with blood pressure variation in 15?914 individuals of African ancestry. J Hypertens 35:1381-1389
Lieberman, Richard; Armeli, Stephen; Scott, Denise M et al. (2016) FKBP5 genotype interacts with early life trauma to predict heavy drinking in college students. Am J Med Genet B Neuropsychiatr Genet 171:879-87
Christensen, Kurt D; Roberts, J Scott; Whitehouse, Peter J et al. (2016) Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 164:155-63
Armeli, Stephen; O'Hara, Ross E; Covault, Jon et al. (2016) Episode-specific drinking-to-cope motivation and next-day stress-reactivity. Anxiety Stress Coping 29:673-84

Showing the most recent 10 out of 205 publications